1. GSK3β: A ray of hope for the treatment of diabetic kidney disease.
- Author
-
Liang LL, He MF, Zhou PP, Pan SK, Liu DW, and Liu ZS
- Subjects
- Humans, Glucose metabolism, Kidney metabolism, Diabetes Mellitus, Diabetic Nephropathies drug therapy, Glycogen Synthase Kinase 3 beta metabolism
- Abstract
Diabetic kidney disease (DKD), a major microvascular complication of diabetes, is characterized by its complex pathogenesis, high risk of chronic renal failure, and lack of effective diagnosis and treatment methods. GSK3β (glycogen synthase kinase 3β), a highly conserved threonine/serine kinase, was found to activate glycogen synthase. As a key molecule of the glucose metabolism pathway, GSK3β participates in a variety of cellular activities and plays a pivotal role in multiple diseases. However, these effects are not only mediated by affecting glucose metabolism. This review elaborates on the role of GSK3β in DKD and its damage mechanism in different intrinsic renal cells. GSK3β is also a biomarker indicating the progression of DKD. Finally, the protective effects of GSK3β inhibitors on DKD are also discussed., (© 2024 Federation of American Societies for Experimental Biology.)
- Published
- 2024
- Full Text
- View/download PDF